| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1996;94:2807-2816.)
© 1996 American Heart Association, Inc.
Articles |
Carvedilol Produces Dose-Related Improvements in Left Ventricular Function and Survival in Subjects With Chronic Heart Failure
the University of Colorado Health Sciences Center, Denver (M.R.B., W.T.A.), University of Utah Health Sciences Center (E.M.G.), University of North Carolina at Chapel Hill (K.F.A.), Stanford University Hospital, Palo Alto, Calif (M.B.F.), Oregon Health Sciences Center, Portland (R.E.H.), University of Minnesota, Minneapolis (S.H.K.), University of California at Los Angeles Medical Center (K.A.N.), Sharp-Reese Stealy Medical Clinic, San Diego, Calif (H.I.), Nebraska Heart Institute, Lincoln (S.K.), and SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (S.Y., N.S.).
Background We conducted a multicenter, placebo-controlled trial designed to establish the efficacy and safety of carvedilol, a "third-generation" ß-blocking agent with vasodilator properties, in chronic heart failure.
Methods and Results Three hundred forty-five subjects with mild to moderate, stable chronic heart failure were randomized to receive treatment with placebo, 6.25 mg BID carvedilol (low-dose group), 12.5 mg BID carvedilol (medium-dose group), or 25 mg BID carvedilol (high-dose group). After a 2- to 4-week up-titration period, subjects remained on study medication for a period of 6 months. The primary efficacy parameter was submaximal exercise measured by two different techniques, the 6-minute corridor walk test and the 9-minute self-powered treadmill test. Carvedilol had no detectable effect on submaximal exercise as measured by either technique. However, carvedilol was associated with dose-related improvements in LV function (by 5, 6, and 8 ejection fraction [EF] units in the low-, medium-, and high-dose carvedilol groups, respectively, compared with 2 EF units with placebo, P<.001 for linear dose response) and survival (respective crude mortality rates of 6.0%, 6.7%, and 1.1% with increasing doses of carvedilol compared with 15.5% in the placebo group, P<.001). When the three carvedilol groups were combined, the all-cause actuarial mortality risk was lowered by 73% in carvedilol-treated subjects (P<.001). Carvedilol also lowered the hospitalization rate (by 58% to 64%, P=.01) and was generally well tolerated.
Conclusions In subjects with mild to moderate heart failure from systolic dysfunction, carvedilol produced dose-related improvements in LV function and dose-related reductions in mortality and hospitalization rate.
Key Words: carvedilol • heart failure • exercise • vasodilation • receptors, adrenergic, beta
This article has been cited by other articles:
 |
|
 |
|
  M. St. John Sutton, S. Ghio, T. Plappert, L. Tavazzi, L. Scelsi, C. Daubert, W. T. Abraham, M. R. Gold, C. Hassager, J. M. Herre, et al. Cardiac Resynchronization Induces Major Structural and Functional Reverse Remodeling in Patients With New York Heart Association Class I/II Heart Failure Circulation, November 10, 2009; 120(19): 1858 - 1865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Duda, K. M. O'Shea, and W. C. Stanley {omega}-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential Cardiovasc Res, October 1, 2009; 84(1): 33 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Klapholz {beta}-Blocker Use for the Stages of Heart Failure Mayo Clin. Proc., August 1, 2009; 84(8): 718 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. McAlister, N. Wiebe, J. A. Ezekowitz, A. A. Leung, and P. W. Armstrong Meta-analysis: {beta}-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure Ann Intern Med, June 2, 2009; 150(11): 784 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghio, N. Freemantle, L. Scelsi, A. Serio, G. Magrini, M. Pasotti, A. Shankar, J. G.F. Cleland, and L. Tavazzi Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial Eur J Heart Fail, May 1, 2009; 11(5): 480 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]
|
|
|
|
|
|
2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]
|
|
|
|
|
|
A. Mebazaa, M. S. Nieminen, G. S. Filippatos, J. G. Cleland, J. E. Salon, R. Thakkar, R. J. Padley, B. Huang, and A. Cohen-Solal Levosimendan vs. dobutamine: outcomes for acute heart failure patients on {beta}-blockers in SURVIVE Eur J Heart Fail, March 1, 2009; 11(3): 304 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Willenheimer The current role of beta-blockers in chronic heart failure: with special emphasis on the CIBIS III trial Eur. Heart J. Suppl., March 1, 2009; 11(suppl_A): A15 - A20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Parissis, M. Nikolaou, D. Farmakis, I. A. Paraskevaidis, V. Bistola, K. Venetsanou, D. Katsaras, G. Filippatos, and D. T. Kremastinos Self-assessment of health status is associated with inflammatory activation and predicts long-term outcomes in chronic heart failure Eur J Heart Fail, February 1, 2009; 11(2): 163 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Naya, T. Tsukamoto, K. Morita, C. Katoh, K. Nishijima, H. Komatsu, S. Yamada, Y. Kuge, N. Tamaki, and H. Tsutsui Myocardial {beta}-Adrenergic Receptor Density Assessed by 11C-CGP12177 PET Predicts Improvement of Cardiac Function After Carvedilol Treatment in Patients with Idiopathic Dilated Cardiomyopathy J. Nucl. Med., February 1, 2009; 50(2): 220 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Kwon, C. M. Halley, T. P. Carrigan, V. Zysek, Z. B. Popovic, R. Setser, P. Schoenhagen, R. C. Starling, S. D. Flamm, and M. Y. Desai Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. J. Am. Coll. Cardiol. Img., January 1, 2009; 2(1): 34 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. R. B. M. van Gestel, S. E. Hoeks, D. D. Sin, G. M. J. M. Welten, O. Schouten, H. J. Witteveen, C. Simsek, H. Stam, F. W. Mertens, J. J. Bax, et al. Impact of Cardioselective {beta}-Blockers on Mortality in Patients with Chronic Obstructive Pulmonary Disease and Atherosclerosis Am. J. Respir. Crit. Care Med., October 1, 2008; 178(7): 695 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nishio, Y. Sakata, T. Mano, T. Ohtani, Y. Takeda, T. Miwa, M. Hori, T. Masuyama, T. Kondo, and K. Yamamoto Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats Eur J Heart Fail, May 1, 2008; 10(5): 446 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Moertl, A. Hammer, M. Huelsmann, R. Pacher, and R. Berger Prognostic value of sequential measurements of amino-terminal prohormone of B-type natriuretic peptide in ambulatory heart failure patients Eur J Heart Fail, April 1, 2008; 10(4): 404 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, V. De Arcangelis, X. Gao, B. Ramani, Y.-s. Jung, and Y. Xiang Norepinephrine- and Epinephrine-induced Distinct 2-Adrenoceptor Signaling Is Dictated by GRK2 Phosphorylation in Cardiomyocytes J. Biol. Chem., January 25, 2008; 283(4): 1799 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Muthumala, F. Drenos, P. M. Elliott, and S. E. Humphries Role of {beta} adrenergic receptor polymorphisms in heart failure: Systematic review and meta-analysis Eur J Heart Fail, January 1, 2008; 10(1): 3 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Albert Switching to Once-Daily Evidence-Based -Blockers in Patients With Systolic Heart Failure or Left Ventricular Dysfunction After Myocardial Infarction Crit. Care Nurse, December 1, 2007; 27(6): 62 - 72. [Full Text] [PDF]
|
|
|
|
|
|
C. Leclercq, G. B. Bleeker, C. Linde, E. Donal, J. J. Bax, M. J. Schalij, and C. Daubert Cardiac resynchronization therapy: clinical results and evolution of candidate selection Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I94 - I106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Shaddy, M. M. Boucek, D. T. Hsu, R. J. Boucek, C. E. Canter, L. Mahony, R. D. Ross, E. Pahl, E. D. Blume, D. A. Dodd, et al. Carvedilol for Children and Adolescents With Heart Failure: A Randomized Controlled Trial JAMA, September 12, 2007; 298(10): 1171 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chen, R. Chang, B. Umakanthan, L. N. Stoletniy, and J. T. Heywood Improvement of Cardiac Function Persists Long Term With Medical Therapy for Left Ventricular Systolic Dysfunction Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 220 - 226. [Abstract] [PDF]
|
|
|
|
|
|
D. Dobre, D. J. van Veldhuisen, M. J.L. deJongste, and F. M. Haaijer-Ruskamp Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival Eur J Heart Fail, September 1, 2007; 9(9): 962 - 963. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fenton and M. Burch Understanding chronic heart failure Arch. Dis. Child., September 1, 2007; 92(9): 812 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Hypertension, August 1, 2007; 50(2): e28 - e55. [Full Text] [PDF]
|
|
|
|
|
|
C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Circulation, May 29, 2007; 115(21): 2761 - 2788. [Full Text] [PDF]
|
|
|
|
|
|
R. Berger, D. Moertl, M. Huelsmann, A. Bojic, R. Ahmadi, I. Heissenberger, and R. Pacher Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure Eur J Heart Fail, February 1, 2007; 9(2): 202 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Abdulla, L. Kober, E. Christensen, and C. Torp-Pedersen Effect of beta-blocker therapy on functional status in patients with heart failure -- A meta-analysis Eur J Heart Fail, August 1, 2006; 8(5): 522 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Butler, J. B. Young, W. T. Abraham, R. C. Bourge, K. F. Adams Jr, R. Clare, C. O'Connor, and for the ESCAPE Investigators Beta-Blocker Use and Outcomes Among Hospitalized Heart Failure Patients J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2462 - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Feldman The Timing for Transplantation: Superior Genetics or Social Prejudice? J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2243 - 2244. [Full Text] [PDF]
|
|
|
|
|
|
K. S. Chong, R. S. Gardner, J. J. Morton, E. A. Ashley, and T. A. McDonagh Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure Eur J Heart Fail, June 1, 2006; 8(4): 355 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lainscak and I. Keber Patients' knowledge and beta blocker treatment improve prognosis of patients from a heart failure clinic Eur J Heart Fail, March 1, 2006; 8(2): 187 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shigeyama, Y. Yasumura, A. Sakamoto, Y. Ishida, T. Fukutomi, M. Itoh, K. Miyatake, and M. Kitakaze Increased gene expression of collagen Types I and III is inhibited by {beta}-receptor blockade in patients with dilated cardiomyopathy Eur. Heart J., December 2, 2005; 26(24): 2698 - 2705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Castro, J. L. Vukasovic, M. Chiong, G. Diaz-Araya, H. Alcaino, M. Copaja, R. Valenzuela, D. Greig, O. Perez, R. Corbalan, et al. Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure Eur J Heart Fail, October 1, 2005; 7(6): 1033 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-L. Sun, S.-J. Hu, L.-H. Wang, Y. Hu, and J.-Y. Zhou Effect of {beta}-Blockers on Cardiac Function and Calcium Handling Protein in Postinfarction Heart Failure Rats Chest, September 1, 2005; 128(3): 1812 - 1821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mahrholdt, A. Wagner, R. M. Judd, U. Sechtem, and R. J. Kim Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies Eur. Heart J., August 1, 2005; 26(15): 1461 - 1474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K.A. Witte, S. Thackray, N. P. Nikitin, J. G.F. Cleland, and A. L. Clark The effects of long-term {beta}-blockade on the ventilatory responses to exercise in chronic heart failure Eur J Heart Fail, June 1, 2005; 7(4): 612 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Edes, Z. Gasior, and K. Wita Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study Eur J Heart Fail, June 1, 2005; 7(4): 631 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O'Meara, E. Lewis, C. Granger, M. E. Dunlap, R. S. McKelvie, J. L. Probstfield, J. B. Young, E. L. Michelson, J. Ostergren, J. Carlsson, et al. Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme Eur J Heart Fail, June 1, 2005; 7(4): 650 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Mann and M. R. Bristow Mechanisms and Models in Heart Failure: The Biomechanical Model and Beyond Circulation, May 31, 2005; 111(21): 2837 - 2849. [Full Text] [PDF]
|
|
|
|
|
|
L. G. Olsson, K. Swedberg, A. L. Clark, K. K. Witte, and J. G.F. Cleland Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review Eur. Heart J., April 2, 2005; 26(8): 778 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-M. Yu, Q. Zhang, J. W.-H. Fung, H. C.-K. Chan, Y.-S. Chan, G. W.-K. Yip, S.-L. Kong, H. Lin, Y. Zhang, and J. E. Sanderson A novel tool to assess systolic asynchrony and identify responders of cardiac resynchronization therapy by tissue synchronization imaging J. Am. Coll. Cardiol., March 1, 2005; 45(5): 677 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sliwa, G. R. Norton, N. Kone, G. Candy, J. Kachope, A. J. Woodiwiss, C. Libhaber, P. Sareli, and R. Essop Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1825 - 1830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-a. Koshimizu, G. Tsujimoto, A. Hirasawa, Y. Kitagawa, and A. Tanoue Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human {alpha}1D- and {alpha}1B-adrenergic receptors Cardiovasc Res, September 1, 2004; 63(4): 662 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Sirak, S. Jelic, and T. H. Le Jemtel Therapeutic update: Non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure J. Am. Coll. Cardiol., August 4, 2004; 44(3): 497 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Task Force Members, J. Lopez-Sendo, K. Swedberg, J. McMurray, J. Tamargo, A. P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, et al. Expert consensus document on {beta}-adrenergic receptor blockers: The Task Force on Beta-Blockers of the European Society of Cardiology Eur. Heart J., August 1, 2004; 25(15): 1341 - 1362. [Full Text] [PDF]
|
|
|
|
|
|
C. Ward The quality of life in heart failure Just talking about it will not make it better Eur J Heart Fail, August 1, 2004; 6(5): 535 - 537. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Chatterjee The Fear of {beta}-Blocker Therapy in Heart Failure: Time to Forget Arch Intern Med, July 12, 2004; 164(13): 1370 - 1371. [Full Text] [PDF]
|
|
|
|
|
|
D. T. Ko, P. R. Hebert, C. S. Coffey, J. P. Curtis, J. M. Foody, A. Sedrakyan, and H. M. Krumholz Adverse Effects of {beta}-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials Arch Intern Med, July 12, 2004; 164(13): 1389 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Shah, M K Davies, D Cartwright, and P Nightingale Management of chronic heart failure in the community: role of a hospital based open access heart failure service Heart, July 1, 2004; 90(7): 755 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N G Bellenger, K Rajappan, S L Rahman, A Lahiri, U Raval, J Webster, G D Murray, A J S Coats, J G F Cleland, and D J Pennell Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study Heart, July 1, 2004; 90(7): 760 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. C. Hoppe Beta-blocker induced bradycardia--should we pace? Eur J Heart Fail, June 1, 2004; 6(4): 449 - 451. [Full Text] [PDF]
|
|
|
|
|
|
M. A Movsesian Altered cAMP-mediated signalling and its role in the pathogenesis of dilated cardiomyopathy Cardiovasc Res, June 1, 2004; 62(3): 450 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Booth, E. E. Ward, K. C. Colgan, B. L. Funk, H. El-Moalem, M. P. Smith, C. Milano, P. K. Smith, M. F. Newman, and D. A. Schwinn Metoprolol and Coronary Artery Bypass Grafting Surgery: Does Intraoperative Metoprolol Attenuate Acute {beta}-Adrenergic Receptor Desensitization During Cardiac Surgery? Anesth. Analg., May 1, 2004; 98(5): 1224 - 1231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tandon, F. A. McAlister, R. T. Tsuyuki, M. Hervas-Malo, R. Dupuit, J. Ezekowitz, B. Cujec, and P. W. Armstrong The Use of {beta}-Blockers in a Tertiary Care Heart Failure Clinic: Dosing, Tolerance, and Outcomes Arch Intern Med, April 12, 2004; 164(7): 769 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Butler, G. Khadim, K. M. Paul, S. F. Davis, M. W. Kronenberg, D. B. Chomsky, R. N. Pierson III, and J. R. Wilson Selection of patients for heart transplantationin the current era of heart failure therapy J. Am. Coll. Cardiol., March 3, 2004; 43(5): 787 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Penicka, J. Bartunek, B. De Bruyne, M. Vanderheyden, M. Goethals, M. De Zutter, P. Brugada, and P. Geelen Improvement of Left Ventricular Function After Cardiac Resynchronization Therapy Is Predicted by Tissue Doppler Imaging Echocardiography Circulation, March 2, 2004; 109(8): 978 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.A. Mehta, S. McDonagh, P.A. Poole-Wilson, R. Grocott-Mason, and S.W. Dubrey Heart failure in a district general hospital: are target doses of beta-blockers realistic? QJM, March 1, 2004; 97(3): 133 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Krum and D. Hare Correspondence Eur. Heart J., February 1, 2004; 25(3): 277 - 277. [Full Text] [PDF]
|
|
|
|
|
|
P. de Groote, N. Helbecque, N. Lamblin, X. Hermant, P. Amouyel, C. Bauters, and J. Dallongeville Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure Eur J Heart Fail, January 1, 2004; 6(1): 17 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ahmed Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure Eur J Heart Fail, December 1, 2003; 5(6): 709 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zanolla and P. Zardini Selection of endpoints for heart failure clinical trials Eur J Heart Fail, December 1, 2003; 5(6): 717 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R S Gardner, W Martin, R Carter, and T A McDonagh Importance of {beta} blockade in the treatment of advanced heart failure Heart, December 1, 2003; 89(12): 1442 - 1444. [Full Text] [PDF]
|
|
|
|
|
|
D. Bello, D. J. Shah, G. M. Farah, S. Di Luzio, M. Parker, M. R. Johnson, W. G. Cotts, F. J. Klocke, R. O. Bonow, R. M. Judd, et al. Gadolinium Cardiovascular Magnetic Resonance Predicts Reversible Myocardial Dysfunction and Remodeling in Patients With Heart Failure Undergoing {beta}-Blocker Therapy Circulation, October 21, 2003; 108(16): 1945 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Warner Stevenson The points for pacing J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1460 - 1462. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Okumura, G. Takagi, J.-i. Kawabe, G. Yang, M.-C. Lee, C. Hong, J. Liu, D. E. Vatner, J. Sadoshima, S. F. Vatner, et al. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload PNAS, August 19, 2003; 100(17): 9986 - 9990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Au, E. M. Udris, V. S. Fan, J. R. Curtis, M. B. McDonell, and S. D. Fihn Risk of Mortality and Heart Failure Exacerbations Associated With Inhaled {beta}-Adrenoceptor Agonists Among Patients With Known Left Ventricular Systolic Dysfunction Chest, June 1, 2003; 123(6): 1964 - 1969. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bouzamondo, J.-S. Hulot, P. Sanchez, and P. Lechat Beta-blocker benefit according to severity of heart failure Eur J Heart Fail, June 1, 2003; 5(3): 281 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jessup and S. Brozena Heart Failure N. Engl. J. Med., May 15, 2003; 348(20): 2007 - 2018. [Full Text] [PDF]
|
|
|
|
 |
|
 H. J Tangeman and J H. Patterson Extended-Release Metoprolol Succinate in Chronic Heart Failure Ann. Pharmacother., May 1, 2003; 37(5): 701 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gheorghiade, W. S. Colucci, and K. Swedberg {beta}-Blockers in Chronic Heart Failure Circulation, April 1, 2003; 107(12): 1570 - 1575. [Full Text] [PDF]
|
|
|
|
|
|
T. Simon, M. Mary-Krause, C. Funck-Brentano, Ph. Lechat, P. Jaillon, and on behalf of CIBIS II investigators Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II) Eur. Heart J., March 2, 2003; 24(6): 552 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A P Maggioni, G Sinagra, C Opasich, E Geraci, M Gorini, E Gronda, D Lucci, G Tognoni, E Balli, and L Tavazzi Treatment of chronic heart failure with {beta} adrenergic blockade beyond controlled clinical trials: the BRING-UP experience Heart, March 1, 2003; 89(3): 299 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Krum, E. B. Roecker, P. Mohacsi, J. L. Rouleau, M. Tendera, A. J. S. Coats, H. A. Katus, M. B. Fowler, M. Packer, and for the Carvedilol Prospective Randomized Cumulati Effects of Initiating Carvedilol in Patients With Severe Chronic Heart Failure: Results From the COPERNICUS Study JAMA, February 12, 2003; 289(6): 712 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Agostoni, M. Guazzi, M. Bussotti, S. De Vita, and P. Palermo Carvedilol Reduces the Inappropriate Increase of Ventilation During Exercise in Heart Failure Patients Chest, December 1, 2002; 122(6): 2062 - 2067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Staudt, M. Bohm, F. Knebel, Y. Grosse, C. Bischoff, A. Hummel, J. B. Dahm, A. Borges, N. Jochmann, K. D. Wernecke, et al. Potential Role of Autoantibodies Belonging to the Immunoglobulin G-3 Subclass in Cardiac Dysfunction Among Patients With Dilated Cardiomyopathy Circulation, November 5, 2002; 106(19): 2448 - 2453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Kukin {beta}-Blockers in Chronic Heart Failure: Considerations for Selecting an Agent Mayo Clin. Proc., November 1, 2002; 77(11): 1199 - 1206. [Abstract] [PDF]
|
|
|
|
 |
|
 J. R. R. Heyen, E. R. Blasi, K. Nikula, R. Rocha, H. A. Daust, G. Frierdich, J. F. Van Vleet, P. De Ciechi, E. G. McMahon, and A. E. Rudolph Structural, functional, and molecular characterization of the SHHF model of heart failure Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1775 - H1784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Spyrou, S. D. Rosen, F. Fath-Ordoubadi, R. Jagathesan, R. Foale, J. S. Kooner, and P. G. Camici Myocardial beta-adrenoceptor densityone month after acute myocardial infarctionpredicts left ventricular volumes at six months J. Am. Coll. Cardiol., October 2, 2002; 40(7): 1216 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wikstrand, A. k. Hjalmarson, F. Waagstein, B. j. Fagerberg, S. Goldstein, J. Kjekshus, H. Wedel, and MERIT-HF Study Group Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: Analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF) J. Am. Coll. Cardiol., August 7, 2002; 40(3): 491 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. V. Bobadilla Current research on carvedilol in heart failure Crit. Care Nurse, August 1, 2002; 22(4): 14 - 16. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Pritchett and M. M. Redfield {beta}-Blockers: New Standard Therapy for Heart Failure Mayo Clin. Proc., August 1, 2002; 77(8): 839 - 846. [Abstract] [PDF]
|
|
|
|
|
|
J. M. Hare Cardiac-Resynchronization Therapy for Heart Failure N. Engl. J. Med., June 13, 2002; 346(24): 1902 - 1905. [Full Text] [PDF]
|
|
|
|
|
|
C. Zugck, A. Haunstetter, C. Kruger, R. Kell, D. Schellberg, W. Kubler, and M. Haass Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure J. Am. Coll. Cardiol., May 15, 2002; 39(10): 1615 - 1622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Lowes, E. M. Gilbert, W. T. Abraham, W. A. Minobe, P. Larrabee, D. Ferguson, E. E. Wolfel, J. Lindenfeld, T. Tsvetkova, A. D. Robertson, et al. Myocardial Gene Expression in Dilated Cardiomyopathy Treated with Beta-Blocking Agents N. Engl. J. Med., May 2, 2002; 346(18): 1357 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Taccetta-Chapnick Using Carvedilol to Treat Heart Failure Crit. Care Nurse, April 1, 2002; 22(2): 36 - 58. [Full Text] [PDF]
|
|
|
|
|
|
P. Merlet, L. Hittinger, J. L. Dubois-Rande, and A. Castaigne Myocardial Adrenergic Dysinnervation in Dilated Cardiomyopathy: Cornerstone or Epiphenomenon? J. Nucl. Med., April 1, 2002; 43(4): 536 - 539. [Full Text] [PDF]
|
|
|
|
|
|
B. Riegel, B. Carlson, Z. Kopp, B. LePetri, D. Glaser, and A. Unger Effect of a Standardized Nurse Case-Management Telephone Intervention on Resource Use in Patients With Chronic Heart Failure Arch Intern Med, March 25, 2002; 162(6): 705 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Foody, M. H. Farrell, and H. M. Krumholz {beta}-Blocker Therapy in Heart Failure: Scientific Review JAMA, February 20, 2002; 287(7): 883 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Farrell, J. M. Foody, and H. M. Krumholz {beta}-Blockers in Heart Failure: Clinical Applications JAMA, February 20, 2002; 287(7): 890 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nohria, E. Lewis, and L. W. Stevenson Medical Management of Advanced Heart Failure JAMA, February 6, 2002; 287(5): 628 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Massie Neurohormonal blockade in chronic heart failure: How much is enough? can there be too much? J. Am. Coll. Cardiol., January 2, 2002; 39(1): 79 - 82. [Full Text] [PDF]
|
|
|
|
 |
|
 S.M. DALLABRIDA and M.A. RUPNICK Vascular Endothelium in Tissue Remodeling: Implications for Heart Failure Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 417 - 428. [Abstract] [PDF]
|
|
|
|
|
|
S. Reiken, M. Gaburjakova, J. Gaburjakova, K.-l. He, A. Prieto, E. Becker, G.-h. Yi, J. Wang, D. Burkhoff, and A. R. Marks {beta}-Adrenergic Receptor Blockers Restore Cardiac Calcium Release Channel (Ryanodine Receptor) Structure and Function in Heart Failure Circulation, December 4, 2001; 104(23): 2843 - 2848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lindenfeld, A. D. Robertson, B. D. Lowes, M. R. Bristow, and for the MOCHA Investigators Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1950 - 1956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Stellbrink, O.-A. Breithardt, A. Franke, S. Sack, P. Bakker, A. Auricchio, T. Pochet, R. Salo, A. Kramer, and J. Spinelli Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1957 - 1965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kubo, E. R. Azevedo, G. E. Newton, J. D. Parker, and J. S. Floras Lack of evidence for peripheral alpha1- adrenoceptor blockade during long-term treatment of heart failure with carvedilol J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1463 - 1469. [Abstract] [Full Text] [PDF]
|
|